$MD

Pediatrix Medical Group (MD) has seen a 24.8% year-to-date stock price increase despite concerns over declining revenue and demand for its neonatal and pediatric healthcare services. The company's 1-year total shareholder return is 56.2%, though its 5-year return is down 23.05%. Analysts debate its valuation, with some suggesting it is 1% overvalued at $26.33, while others argue it is undervalued at $58.51. The company faces challenges from portfolio restructuring and rising salary costs.

Morgan Stanley downgraded Baidu (BIDU) to Underweight, cutting its price target to $80. CIBC downgraded Bank of Montreal (BMO) to Neutral, raising its target to C$272. JP Morgan downgraded Cogent Communications (CCOI) to Underweight, lowering its target to $9. Jefferies downgraded Pediatrix Medical Group (MD) to Hold, raising its target to $28. UBS downgraded Core Natural Resources (CNR) to Neutral, raising its target to $105.

Pediatrix Medical Group (MD) shares fell 1.2% in pre-market trading after Jefferies downgraded the stock from Buy to Hold, citing limited upside potential. The firm raised its price target to $28 but noted shares are near their 52-week high. Jefferies highlighted the stock's 150% advance over two years and anticipated headwinds from Affordable Care Act changes. Pediatrix recently reported Q2 2026 earnings beating estimates but maintained its full-year EBITDA guidance.

Young Sylvia Jean sold (to issuer) 18,500 shares of Pediatrix Medical Group, Inc. (MD) at $26.62 ($0.49M total) on 2026-08-14.

Midland Exploration Inc. (TSX-V: MD) said it and SOQUEM will start a follow-up exploration at the Malaco Mountain copper-gold-REE project in Quebec, including a 15-line km induced polarization survey plus prospecting and soil sampling. Midland cited 2025 grab-sample results up to 31.60% Cu and 6.92 g/t Au. The 2026 alliance budget is $1 million.

Pediatrix Medical Group (MD) reported Q2 2026 revenue of $487.8 million, up 4% y/y, with adjusted EPS of $0.63 and adjusted EBITDA of $76.4 million. Net income was $39.8 million. Patient volume fell 2.1% y/y, while same-unit pricing rose 4%. CFO Rossi reaffirmed full-year 2026 adjusted EBITDA guidance of $280 million to $300 million.

Pediatrix Medical Group, Inc. (MD) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Second Quarter Results FORT LAUDERDALE, Fla., August 4, 2026 - Pediatrix Medical G

Pediatrix Medical Group (NYSE:MD) reported Q2 CY2026 revenue of $487.8 million, up 4% year on year, beating market expectations by 2.1% (per the article). Non-GAAP adjusted EPS was $0.63, up from $0.53, and 6.6% above consensus. Shares fell 12.3% to $23.02 after results. Analysts expect revenue flat and EPS around $2.24 to $2.26.

Pediatrix Medical Group (MD) is set to report Q2 earnings Tuesday before market open. The company previously reported $476.2M revenue, up 3.9% YoY, and beat EPS and slightly topped full-year EBITDA guidance. For Q2, analysts expect 1.9% revenue growth. The stock is down 3.2% over the past month; average price target is $24.50 vs $26.51.

Midland Exploration (TSX-V:MD) started a 2026 exploration program at its Lewis Gold Project in Québec under an option agreement with Barrick Mining (TSX:ABX). The plan covers 154 exclusive rights over about 86 km², including geological mapping and work at Red Giant and Golden Nest, with a second phase in September. Lewis is near the Nelligan deposit with 3.12Moz indicated and 5.16Moz inferred gold.